Antonio Frassoldati

Preoperative Chemotherapy Plus Trastuzumab, Lapatinib, or Both in Human Epidermal Growth Factor Receptor 2–Positive Operable Breast Cancer: Results of the Randomized Phase II CHER-LOB Study

Valentina Guarneri, Antonio Frassoldati, Alberto Bottini et al. · Journal of Clinical Oncology · 2012 · 368 citations · Full text

Medicine, Oncology, Pharmacology +16

Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results

Robert E. Coleman, Richard de Boer, Holger Eidtmann et al. · Annals of Oncology · 2012 · 337 citations · Full text

Medicine, Oncology, Pharmacotherapy +12

Upfront FOLFOXIRI plus bevacizumab and reintroduction after progression versus mFOLFOX6 plus bevacizumab followed by FOLFIRI plus bevacizumab in the treatment of patients with metastatic colorectal cancer (TRIBE2): a multicentre, open-label, phase 3, randomised, controlled trial

Chiara Cremolini, Carlotta Antoniotti, Daniele Rossini et al. · The Lancet Oncology · 2020 · 325 citations · Full text

Medicine, Oncology, Pharmacotherapy +8

Adipose-Derived Mesenchymal Stem Cells as Stable Source of Tumor Necrosis Factor–Related Apoptosis-Inducing Ligand Delivery for Cancer Therapy

Giulia Grisendi, Rita Bussolari, Luigi Cafarelli et al. · Cancer Research · 2010 · 244 citations

Medicine, Cell Biology, Oncology +17

Association of Systemic Inflammation Index and Body Mass Index with Survival in Patients with Renal Cell Cancer Treated with Nivolumab

Ugo De Giorgi, Giuseppe Procopio, Diana Giannarelli et al. · Clinical Cancer Research · 2019 · 239 citations · Full text

Medicine, Immunology, Oncology +17